These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37304541)

  • 21. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629.
    Hughes BGM; Mendoza RG; Basset-Seguin N; Vornicova O; Schachter J; Joshi A; Meyer N; Grange F; Piulats JM; Bauman JR; Chirovsky D; Zhang P; Gumuscu B; Swaby RF; Grob JJ
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1777-1790. PubMed ID: 34558040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study.
    Okada T; Fushimi C; Matsuki T; Tokashiki K; Takahashi H; Okamoto I; Sato H; Kondo T; Hanyu K; Kishida T; Ito T; Yamashita G; Masubuchi T; Tada Y; Miura K; Omura GO; Yamashita T; Oridate N; Tsukahara K
    Anticancer Res; 2023 Jun; 43(6):2717-2724. PubMed ID: 37247908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
    Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW
    Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer.
    Wagner SM; Magnes T; Melchardt T; Kiem D; Weiss L; Neureiter D; Wagner C; Aretin MB; Nemec S; Gamerith G; Pall G; Greil R; Fuereder T
    Anticancer Res; 2023 Mar; 43(3):1273-1282. PubMed ID: 36854497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Nishimura A; Yokota T; Hamauchi S; Onozawa Y; Shirasu H; Kawabata T; Ogawa H; Onoe T; Iida Y; Mukaigawa T; Yasui H
    Int J Clin Oncol; 2021 Oct; 26(10):1822-1830. PubMed ID: 34152533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
    Sheth S; Weiss J
    Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level.
    Giuliani J; Bonetti A
    Oral Oncol; 2019 Oct; 97():143-145. PubMed ID: 31431352
    [No Abstract]   [Full Text] [Related]  

  • 30. Role of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yin G; Guo W; Duan H; Huang Z
    Clin Otolaryngol; 2021 Sep; 46(5):1013-1020. PubMed ID: 33765363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
    Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
    Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
    Desilets A; Soulières D
    Expert Opin Drug Saf; 2020 Aug; 19(8):927-934. PubMed ID: 32458764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.
    Cao Y; Qin S; Luo S; Li Z; Cheng Y; Fan Y; Sun Y; Yin X; Yuan X; Li W; Liu T; Hsu CH; Lin X; Kim SB; Kojima T; Zhang J; Lee SH; Bai Y; Muro K; Doi T; Bai C; Gu K; Pan HM; Bai L; Yang JW; Cui Y; Lu W; Chen J
    ESMO Open; 2022 Feb; 7(1):100341. PubMed ID: 34973513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for head and neck cancer: from recurrent/metastatic disease to (neo)adjuvant treatment in surgically resectable tumors.
    Specenier P
    Curr Opin Otolaryngol Head Neck Surg; 2021 Apr; 29(2):168-177. PubMed ID: 33605624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
    Xin W; Ding H; Fang Q; Zheng X; Tong Y; Xu G; Yang G
    BMJ Open; 2020 Dec; 10(12):e038867. PubMed ID: 33371020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
    Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
    Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Taberna M; Oliva M; Mesía R
    Front Oncol; 2019; 9():383. PubMed ID: 31165040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapeutic Approaches to the Management of Head and Neck Cancer.
    Nan X; Gold KA; Cohen E
    Oncology (Williston Park); 2018 Dec; 32(12):617-9, 625-6. PubMed ID: 30632130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis.
    Clarke E; Eriksen JG; Barrett S
    Acta Oncol; 2021 Nov; 60(11):1534-1542. PubMed ID: 34410881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Zhang X; Rui M; Lin C; Li Z; Wei D; Han R; Ju H; Ren G
    Cancer Med; 2023 Feb; 12(3):2702-2712. PubMed ID: 35975731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.